Streptozocin

Streptozocin
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning See full prescribing information for complete Boxed Warning. Condition Name: ZANOSAR should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and hematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumorigenic or carcinogenic in some rodents. The physician must judge the possible benefit to the patient against the known toxic effects of this drug in considering the advisability of therapy with ZANOSAR. The physician should be familiar with the following text before making a judgment and beginning treatment.

Overview

Streptozocin is an alkylating agent, antineoplastic agent and nitrosourea that is FDA approved for the treatment of metastatic islet cell carcinoma of the pancreas. There is a Black Box Warning for this drug as shown here. Common adverse reactions include nausea, confusion, lethargy and depression.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

ZANOSAR sterile powder should be administered intravenously by rapid injection or short/prolonged infusion. It is not active orally. Although it has been administered intraarterially, this is not recommended pending further evaluation of the possibility that adverse renal effects may be evoked more rapidly by this route of administration.

Two different dosage schedules have been employed successfully with ZANOSAR.

Daily Schedule

• The recommended dose for daily intravenous administration is 500 mg/m2 of body surface area for five consecutive days every six weeks until maximum benefit or until treatment-limiting toxicity is observed. Dose escalation on this schedule is not recommended.

Weekly Schedule

• The recommended initial dose for weekly intravenous administration is 1000 mg/m2 of body surface area at weekly intervals for the first two courses (weeks). In subsequent courses, drug doses may be escalated in patients who have not achieved a therapeutic response and who have not experienced significant toxicity with the previous course of treatment. However, A SINGLE DOSE OF 1500 mg/m2 BODY SURFACE AREA SHOULD NOT BE EXCEEDED as a greater dose may cause azotemia. When administered on this schedule, the median time to onset of response is about 17 days and the median time to maximum response is about 35 days. The median total dose to onset of response is about 2000 mg/m2 body surface area and the median total dose to maximum response is about 4000 mg/m2 body surface area.
• The ideal duration of maintenance therapy with ZANOSAR has not yet been clearly established for either of the above schedules.
• For patients with functional tumors, serial monitoring of fasting insulin levels allows a determination of biochemical response to therapy. For patients with either functional or nonfunctional tumors, response to therapy can be determined by measurable reductions of tumor size (reduction of organomegaly, masses, or lymph nodes).
• Reconstitute ZANOSAR with 9.5 mL of dextrose injection, USP, or 0.9% sodium chloride injection, USP. The resulting pale-gold solution will contain 100 mg of streptozocin and 22 mg of citric acid per mL. Where more dilute infusion solutions are desirable, further dilution in the above vehicles is recommended. The total storage time for streptozocin after it has been placed in solution should not exceed 12 hours. This product contains no preservatives and is not intended as a multiple-dose vial.

Caution in the handling and preparation of the powder and solution should be exercised, and the use of gloves is recommended. If the sterile powder of ZANOSAR or a solution prepared from ZANOSAR contacts the skin or mucosae, immediately wash the affected area with soap and water. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1–7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Streptozocin in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Streptozocin in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Streptozocin FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Streptozocin in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Streptozocin in pediatric patients.

Contraindications

There is limited information regarding Streptozocin Contraindications in the drug label.

Warnings

Warning See full prescribing information for complete Boxed Warning. Condition Name: ZANOSAR should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and hematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumorigenic or carcinogenic in some rodents. The physician must judge the possible benefit to the patient against the known toxic effects of this drug in considering the advisability of therapy with ZANOSAR. The physician should be familiar with the following text before making a judgment and beginning treatment.

There is limited information regarding Streptozocin Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Streptozocin Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Streptozocin Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Streptozocin Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Streptozocin in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Streptozocin in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Streptozocin during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Streptozocin in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Streptozocin in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Streptozocin in geriatric settings.

Gender

There is no FDA guidance on the use of Streptozocin with respect to specific gender populations.

Race

There is no FDA guidance on the use of Streptozocin with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Streptozocin in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Streptozocin in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Streptozocin in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Streptozocin in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Streptozocin Administration in the drug label.

Monitoring

There is limited information regarding Streptozocin Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Streptozocin and IV administrations.

Overdosage

There is limited information regarding Streptozocin overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Streptozocin Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Streptozocin Mechanism of Action in the drug label.

Structure

There is limited information regarding Streptozocin Structure in the drug label.

Pharmacodynamics

There is limited information regarding Streptozocin Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Streptozocin Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Streptozocin Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Streptozocin Clinical Studies in the drug label.

How Supplied

There is limited information regarding Streptozocin How Supplied in the drug label.

Storage

There is limited information regarding Streptozocin Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Streptozocin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Streptozocin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Streptozocin Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Streptozocin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Streptozocin Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Streptozocin Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.